PVCT — PROVECTUS BIOPHARMACEUTICALS, INC.

—
OTC · Health Care · Pharmaceuticals · CIK 315545 ·
Last close
$0.04
Market Cap
$17.90M
52W High
$0.08
52W Low
$0.04
ADV30
135,936
Next earnings
—
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -1,211,365 -1,266,276 467,087 180,733 7,146,156
Jun 2026 — — — — — — —
Mar 2026 0 — -1,247,903 -1,290,454 577,580 223,883 7,308,410
Dec 2025 0 — -1,120,489 -1,239,315 697,502 251,291 7,000,220

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,590,112
Investing CF
—
Financing CF
$2,343,763
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-264,144,266
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,444,727
Pretax Income TTM
$-5,644,471
Interest Exp TTM
$199,744
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-4,419,621
Free Cash Flow
$-2,503,259
Enterprise Value
$20,584,446
Total Cash
$180,733
Total Debt
$2,907,206
Shares Out
420,279,879
Trailing EPS
$-0.01
Book Value
$-0.02
ROE
—
ROA
-623.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -5,294,765 -5,505,124 697,502 7,000,220 -6,298,737 -3,325,991
Dec 2024 0 -4,531,603 -4,762,137 1,006,259 6,975,484 -5,959,332 -3,284,091
Dec 2023 0 -2,925,477 -3,101,768 1,448,843 9,042,194 -7,593,351 -2,571,978
Dec 2022 0 -3,428,379 -3,554,683 2,037,246 8,265,756 -6,228,510 -3,041,472

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-4,749,343
OpCashFlow TTM
—
Assets (Latest)
$1,473,501
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LPCN Lipocine Inc. $17.72M $1.60 —
CELU Celularity Inc $18.53M $0.57 —
EDSA Edesa Biotech, Inc. $18.90M $1.96 —
ATOS ATOSSA THERAPEUTICS, INC. $18.96M $1.90 —
IGC IGC Pharma, Inc. $19.43M $0.19 —

News headlines (Yahoo Finance, 1h cache)

Provectus: Q3 Earnings Snapshot
2026-11-10 20:05 · Yahoo
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
2026-07-07 12:00 · Yahoo
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
2026-06-30 12:00 · Yahoo
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
2026-06-25 12:00 · Yahoo
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
2026-05-18 12:00 · Yahoo
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
2026-04-20 22:09 · Yahoo
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium
2026-05-04 12:00 · Yahoo
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
2026-04-02 12:00 · Yahoo
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
2026-07-22 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.